The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained

Cell Calcium

Volumn 60, Issue 3, 2016, Pages 218-234

  Joshi, Amit U ^a   Kornfeld, Opher S ^a   Mochly Rosen, Daria ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium; ER; Mitochondria; Mitochondrial dynamics; Mitochondrial transport; Neurodegeneration; UPR

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM CHANNEL; CALCIUM CHANNEL L TYPE; CURCUMIN; CYCLOSPORIN A; DEXPRAMIPEXOLE; DIMEBON; IONOTROPIC RECEPTOR; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NORPHENAZONE; PRAMIPEXOLE; THIOCTIC ACID; UBIQUINONE; CALCIUM; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; AUTOOXIDATION; CALCIUM TRANSPORT; CELL ORGANELLE; CELL SURVIVAL; DEGENERATIVE DISEASE; ENDOPLASMIC RETICULUM MEMBRANE; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; ANIMAL; DRUG DEVELOPMENT; ENDOPLASMIC RETICULUM; METABOLISM; PATHOLOGY;

ANIMALS; CALCIUM; DRUG DISCOVERY; ENDOPLASMIC RETICULUM; HUMANS; MITOCHONDRIA; NERVE DEGENERATION; REACTIVE OXYGEN SPECIES;

EID: 84975466642     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2016.04.010     Document Type: Review

References (231)

1. [1] Scheper, W., Hoozemans, J.J., The unfolded protein response in neurodegenerative diseases: a neuropathological perspective. Acta Neuropathol. (Berl.) 130:3 (2015), 315–331, 10.1007/s00401-015-1462-8 (PubMed PMID: 26210990 PubMed Central PMCID: PMC4541706).
2. [2] Schroder, M., Kaufman, R.J., ER stress and the unfolded protein response. Mutat. Res. 569:1-2 (2005), 29–63, 10.1016/j.mrfmmm.2004.06.056 (PubMed PMID: 15603751).
3. [3] Hetz, C., The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13:2 (2012), 89–102, 10.1038/nrm3270 (PubMed PMID: 22251901).
4. [4] Hampton, R.Y., ER stress response: getting the UPR hand on misfolded proteins. Curr. Biol. 10:14 (2000), R518–R521 (PubMed PMID: 10898996).
5. [5] Boyce, M., Bryant, K.F., Jousse, C., Long, K., Harding, H.P., Scheuner, D., Kaufman, R.J., Ma, D., Coen, D.M., Ron, D., Yuan, J., A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307:5711 (2005), 935–939, 10.1126/science.1101902 (PubMed PMID: 15705855).
6. [6] Ye, J., Rawson, R.B., Komuro, R., Chen, X., Dave, U.P., Prywes, R., Brown, M.S., Goldstein, J.L., ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol. Cell 6:6 (2000), 1355–1364 (PubMed PMID: 11163209).
7. [7] Meusser, B., Hirsch, C., Jarosch, E., Sommer, T., ERAD: the long road to destruction. Nat. Cell Biol. 7:8 (2005), 766–772, 10.1038/ncb0805-766 (PubMed PMID: 16056268).
8. [8] Chen, Y., Brandizzi, F., IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 23:11 (2013), 547–555, 10.1016/j.tcb.2013.06.005 (PubMed PMID: 23880584 PubMed Central PMCID: PMC3818365).
9. [9] Fonseca, A.C., Ferreiro, E., Oliveira, C.R., Cardoso, S.M., Pereira, C.F., Activation of the endoplasmic reticulum stress response by the amyloid-beta 1–40 peptide in brain endothelial cells. Biochim. Biophys. Acta 1832:12 (2013), 2191–2203, 10.1016/j.bbadis.2013.08.007 (PubMed PMID: 23994613).
10. [10] Matus, S., Glimcher, L.H., Hetz, C., Protein folding stress in neurodegenerative diseases: a glimpse into the ER. Curr. Opin. Cell Biol. 23:2 (2011), 239–252, 10.1016/j.ceb.2011.01.003 (PubMed PMID: 21288706).
11. [11] Lindholm, D., Wootz, H., Korhonen, L., ER stress and neurodegenerative diseases. Cell Death Differ. 13:3 (2006), 385–392, 10.1038/sj.cdd.4401778 (PubMed PMID: 16397584).
12. [12] Guo, X., Disatnik, M.H., Monbureau, M., Shamloo, M., Mochly-Rosen, D., Qi, X., Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J. Clin. Invest. 123:12 (2013), 5371–5388, 10.1172/JCI70911 (PubMed PMID: 24231356 PubMed Central PMCID: PMC3859413).
13. [13] Cattaneo, E., Zuccato, C., Tartari, M., Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6:12 (2005), 919–930, 10.1038/nrn1806 (PubMed PMID: 16288298).
14. [14] Vidal, R., Caballero, B., Couve, A., Hetz, C., Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. Curr. Mol. Med. 11:1 (2011), 1–12 (PubMed PMID: 21189122).
15. [15] Carnemolla, A., Fossale, E., Agostoni, E., Michelazzi, S., Calligaris, R., De Maso, L., Del Sal, G., MacDonald, M.E., Persichetti, F., Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 284:27 (2009), 18167–18173, 10.1074/jbc.M109.018325 (PubMed PMID: 19433866 PubMed Central PMCID: PMC2709382).
16. [16] Cho, K.J., Lee, B.I., Cheon, S.Y., Kim, H.W., Kim, H.J., Kim, G.W., Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease. Neuroscience 163:4 (2009), 1128–1134, 10.1016/j.neuroscience.2009.07.048 (PubMed PMID: 19646509).
17. [17] Duennwald, M.L., Lindquist, S., Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev. 22:23 (2008), 3308–3319, 10.1101/gad.1673408 (PubMed PMID: 19015277 PubMed Central PMCID: PMC2600758).
18. [18] Zuleta, A., Vidal, R.L., Armentano, D., Parsons, G., Hetz, C., AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington's disease. Biochem. Biophys. Res. Commun. 420:3 (2012), 558–563, 10.1016/j.bbrc.2012.03.033 (PubMed PMID: 22445760).
19. [19] Vidal, R.L., Figueroa, A., Court, F.A., Thielen, P., Molina, C., Wirth, C., Caballero, B., Kiffin, R., Segura-Aguilar, J., Cuervo, A.M., Glimcher, L.H., Hetz, C., Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. Hum. Mol. Genet. 21:10 (2012), 2245–2262, 10.1093/hmg/dds040 (PubMed PMID: 22337954 PubMed Central PMCID: PMC3335312).
20. [20] Lajoie, P., Snapp, E.L., Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin. J. Cell Sci. 124:Pt. 19 (2011), 3332–3343, 10.1242/jcs.087510 (PubMed PMID: 21896647; PubMed Central PMCID: PMC3178454).
21. [21] Jiang, Y., Lv, H., Liao, M., Xu, X., Huang, S., Tan, H., Peng, T., Zhang, Y., Li, H., GRP78 counteracts cell death and protein aggregation caused by mutant huntingtin proteins. Neurosci. Lett. 516:2 (2012), 182–187, 10.1016/j.neulet.2012.03.074 (PubMed PMID: 22490889).
22. [22] Noh, J.Y., Lee, H., Song, S., Kim, N.S., Im, W., Kim, M., Seo, H., Chung, C.W., Chang, J.W., Ferrante, R.J., Yoo, Y.J., Ryu, H., Jung, Y.K., SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. J. Biol. Chem. 284:17 (2009), 11318–11325, 10.1074/jbc.M807620200 (PubMed PMID: 19240033 PubMed Central PMCID: PMC2670137).
23. [23] Katayama, T., Imaizumi, K., Manabe, T., Hitomi, J., Kudo, T., Tohyama, M., Induction of neuronal death by ER stress in Alzheimer's disease. J. Chem. Neuroanat. 28:1–2 (2004), 67–78, 10.1016/j.jchemneu.2003.12.004 (PubMed PMID: 15363492).
24. [24] Salminen, A., Kauppinen, A., Suuronen, T., Kaarniranta, K., Ojala, J., ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J. Neuroinflammation, 6, 2009, 41, 10.1186/1742-2094-6-41 (PubMedPMID:20035627;PubMedCentralPMCID:PMC2806266).
25. [25] Nijholt, D.A., de Graaf, T.R., van Haastert, E.S., Oliveira, A.O., Berkers, C.R., Zwart, R., Ovaa, H., Baas, F., Hoozemans, J.J., Scheper, W., Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease. Cell Death Differ. 18:6 (2011), 1071–1081, 10.1038/cdd.2010.176 (PubMed PMID: 21252911 PubMed Central PMCID: PMC3131935).
26. [26] Sato, N., Urano, F., Yoon Leem, J., Kim, S.H., Li, M., Donoviel, D., Bernstein, A., Lee, A.S., Ron, D., Veselits, M.L., Sisodia, S.S., Thinakaran, G., Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression. Nat. Cell Biol. 2:12 (2000), 863–870, 10.1038/35046500 (PubMed PMID: 11146649).
27. [27] Prasanthi, J.R., Larson, T., Schommer, J., Ghribi, O., Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus. PLoS One, 6(10), 2011, e26420, 10.1371/journal.pone.0026420 (PubMed PMID: 22046282 PubMed Central PMCID: PMC3194795).
28. [28] Leedo, Y., Lee, K.S., Lee, H.J., Kimdo, H., Noh, Y.H., Yu, K., Jung, H.Y., Lee, S.H., Lee, J.Y., Youn, Y.C., Jeong, Y., Kim, D.K., Lee, W.B., Kim, S.S., Activation of PERK signaling attenuates abeta-mediated ER stress. PLoS One, 5(5), 2010, e10489, 10.1371/journal.pone.0010489 (PubMed PMID: 20463975 PubMed Central PMCID: PMC2864758).
29. [29] Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., Takahashi, K., Asaka, I., Aoi, T., Watanabe, A., Watanabe, K., Kadoya, C., Nakano, R., Watanabe, D., Maruyama, K., Hori, O., Hibino, S., Choshi, T., Nakahata, T., Hioki, H., Kaneko, T., Naitoh, M., Yoshikawa, K., Yamawaki, S., Suzuki, S., Hata, R., Ueno, S., Seki, T., Kobayashi, K., Toda, T., Murakami, K., Irie, K., Klein, W.L., Mori, H., Asada, T., Takahashi, R., Iwata, N., Yamanaka, S., Inoue, H., Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12:4 (2013), 487–496, 10.1016/j.stem.2013.01.009 (PubMed PMID: 23434393).
30. [30] Barbero-Camps, E., Fernandez, A., Baulies, A., Martinez, L., Fernandez-Checa, J.C., Colell, A., Endoplasmic reticulum stress mediates amyloid beta neurotoxicity via mitochondrial cholesterol trafficking. Am. J. Pathol. 184:7 (2014), 2066–2081, 10.1016/j.ajpath.2014.03.014 (PubMed PMID: 24815354 PubMed Central PMCID: PMC4076561).
31. [31] Chung, C.Y., Khurana, V., Auluck, P.K., Tardiff, D.F., Mazzulli, J.R., Soldner, F., Baru, V., Lou, Y., Freyzon, Y., Cho, S., Mungenast, A.E., Muffat, J., Mitalipova, M., Pluth, M.D., Jui, N.T., Schule, B., Lippard, S.J., Tsai, L.H., Krainc, D., Buchwald, S.L., Jaenisch, R., Lindquist, S., Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 342:6161 (2013), 983–987, 10.1126/science.1245296 (PubMed PMID: 24158904 PubMed Central PMCID: PMC4022187).
32. [32] Shulman, J.M., De Jager, P.L., Feany, M.B., Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 6 (2011), 193–222, 10.1146/annurev-pathol-011110-130242 (PubMed PMID: 21034221).
33. [33] Burke, W.J., Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology, 59(7), 2002, 1118 (author reply PubMed PMID: 12370484).
34. [34] Omura, T., Kaneko, M., Okuma, Y., Matsubara, K., Nomura, Y., Endoplasmic reticulum stress and Parkinson's disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid. Med. Cell. Longev., 2013, 2013, 239854, 10.1155/2013/239854.PubMedPMID:23710284;PubMedCentralPMCID:PMC3654363.
35. [35] Mercado, G., Valdes, P., Hetz, C., An ERcentric view of parkinson's disease. Trends Mol. Med. 19:3 (2013), 165–175, 10.1016/j.molmed.2012.12.005 (PubMed PMID: 23352769).
36. [36] Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, R.D., Labaer, J., Rochet, J.C., Bonini, N.M., Lindquist, S., Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313:5785 (2006), 324–328, 10.1126/science.1129462 (PubMed PMID: 16794039 PubMed Central PMCID: PMC1983366).
37. [37] Belal, C., Ameli, N.J., El Kommos, A., Bezalel, S., Al'Khafaji, A.M., Mughal, M.R., Mattson, M.P., Kyriazis, G.A., Tyrberg, B., Chan, S.L., The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant alpha-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins. Hum. Mol. Genet. 21:5 (2012), 963–977, 10.1093/hmg/ddr502 (PubMed PMID: 22045699 PubMed Central PMCID: PMC3277305).
38. [38] Bellucci, A., Navarria, L., Zaltieri, M., Falarti, E., Bodei, S., Sigala, S., Battistin, L., Spillantini, M., Missale, C., Spano, P., Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease. J. Neurochem. 116:4 (2011), 588–605, 10.1111/j.1471-4159.2010.07143.x (PubMed PMID: 21166675).
39. [39] Melrose, H.L., LRRK2 and ubiquitination: implications for kinase inhibitor therapy. Biochem. J. 470:3 (2015), e21–e24, 10.1042/BJ20150785 (PubMed PMID: 26341487 PubMed Central PMCID: PMC4613699).
40. [40] Yuan, Y., Cao, P., Smith, M.A., Kramp, K., Huang, Y., Hisamoto, N., Matsumoto, K., Hatzoglou, M., Jin, H., Feng, Z., Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One, 6(8), 2011, e22354, 10.1371/journal.pone.0022354 (PubMed PMID: 21857923 PubMed Central PMCID: PMC3153934).
41. [41] Esteves, A.R., Cardoso, S.M., LRRK2 at the crossroad between autophagy and microtubule trafficking: insights into parkinson's disease. Neuroscientist, 2016, 10.1177/1073858415616558 (PubMed PMID: 26740081).
42. [42] Gomez-Suaga, P., Luzon-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P.G., Churchill, G.C., Hilfiker, S., Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet. 21:3 (2012), 511–525, 10.1093/hmg/ddr481 (PubMed PMID: 22012985 PubMed Central PMCID: PMC3259011).
43. [43] Cherra, S.J. 3rd, Steer, E., Gusdon, A.M., Kiselyov, K., Chu, C.T., Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am. J. Pathol. 182:2 (2013), 474–484, 10.1016/j.ajpath.2012.10.027 (PubMed PMID: 23231918; PubMed Central PMCID: PMC3562730).
44. [44] Jaronen, M., Goldsteins, G., Koistinaho, J., ER stress and unfolded protein response in amyotrophic lateral sclerosis-a controversial role of protein disulphide isomerase. Front. Cell. Neurosci., 8, 2014, 402, 10.3389/fncel.2014.00402 (PubMedPMID:25520620;PubMedCentralPMCID:PMC4251436).
45. [45] Nishitoh, H., Kadowaki, H., Nagai, A., Maruyama, T., Yokota, T., Fukutomi, H., Noguchi, T., Matsuzawa, A., Takeda, K., Ichijo, H., ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev. 22:11 (2008), 1451–1464, 10.1101/gad.1640108 (PubMed PMID: 18519638 PubMed Central PMCID: PMC2418582).
46. [46] Walker, A.K., Soo, K.Y., Sundaramoorthy, V., Parakh, S., Ma, Y., Farg, M.A., Wallace, R.H., Crouch, P.J., Turner, B.J., Horne, M.K., Atkin, J.D., ALS-associated TDP-43 induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS One, 8(11), 2013, e81170, 10.1371/journal.pone.0081170 (PubMed PMID: 24312274 PubMed Central PMCID: PMC3843686).
47. [47] Wang, L., Popko, B., Roos, R.P., The unfolded protein response in familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 20:5 (2011), 1008–1015, 10.1093/hmg/ddq546 (PubMed PMID: 21159797 PubMed Central PMCID: PMC3033190).
48. [48] Atkin, J.D., Farg, M.A., Turner, B.J., Tomas, D., Lysaght, J.A., Nunan, J., Rembach, A., Nagley, P., Beart, P.M., Cheema, S.S., Horne, M.K., Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1. J. Biol. Chem. 281:40 (2006), 30152–30165, 10.1074/jbc.M603393200 (PubMed PMID: 16847061).
49. [49] Hetz, C., Thielen, P., Matus, S., Nassif, M., Court, F., Kiffin, R., Martinez, G., Cuervo, A.M., Brown, R.H., Glimcher, L.H., XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev. 23:19 (2009), 2294–2306, 10.1101/gad.1830709 (PubMed PMID: 19762508 PubMed Central PMCID: PMC2758741).
50. [50] Farg, M.A., Soo, K.Y., Walker, A.K., Pham, H., Orian, J., Horne, M.K., Warraich, S.T., Williams, K.L., Blair, I.P., Atkin, J.D., Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase. Neurobiol. Aging 33:12 (2012), 2855–2868, 10.1016/j.neurobiolaging.2012.02.009 (PubMed PMID: 22459602).
51. [51] Kiskinis, E., Sandoe, J., Williams, L.A., Boulting, G.L., Moccia, R., Wainger, B.J., Han, S., Peng, T., Thams, S., Mikkilineni, S., Mellin, C., Merkle, F.T., Davis-Dusenbery, B.N., Ziller, M., Oakley, D., Ichida, J., Di Costanzo, S., Atwater, N., Maeder, M.L., Goodwin, M.J., Nemesh, J., Handsaker, R.E., Paull, D., Noggle, S., McCarroll, S.A., Joung, J.K., Woolf, C.J., Brown, R.H., Eggan, K., Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14:6 (2014), 781–795, 10.1016/j.stem.2014.03.004 (PubMed PMID: 24704492 PubMed Central PMCID: PMC4653065).
52. [52] Soo, K.Y., Halloran, M., Sundaramoorthy, V., Parakh, S., Toth, R.P., Southam, K.A., McLean, C.A., Lock, P., King, A., Farg, M.A., Atkin, J.D., Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol. (Berl.) 130:5 (2015), 679–697, 10.1007/s00401-015-1468-2 (PubMed PMID: 26298469).
53. [53] Wang, L., Popko, B., Roos, R.P., An enhanced integrated stress response ameliorates mutant SOD1-induced ALS. Hum. Mol. Genet. 23:10 (2014), 2629–2638, 10.1093/hmg/ddt658 (PubMed PMID: 24368417 PubMed Central PMCID: PMC3990163).
54. [54] Vijayalakshmi, K., Alladi, P.A., Ghosh, S., Prasanna, V.K., Sagar, B.C., Nalini, A., Sathyaprabha, T.N., Raju, T.R., Evidence of endoplasmic reticular stress in the spinal motor neurons exposed to CSF from sporadic amyotrophic lateral sclerosis patients. Neurobiol. Dis. 41:3 (2011), 695–705, 10.1016/j.nbd.2010.12.005 (PubMed PMID: 21168498).
55. [55] Gong, T., Wang, Q., Lin, Z., Chen, M.L., Sun, G.Z., Endoplasmic reticulum (ER) stress inhibitor salubrinal protects against ceramide-induced SH-SY5Y cell death. Biochem. Biophys. Res. Commun. 427:3 (2012), 461–465, 10.1016/j.bbrc.2012.08.068 (PubMed PMID: 22935424).
56. [56] Romero-Ramirez, L., Nieto-Sampedro, M., Barreda-Manso, M.A., All roads go to Salubrinal: endoplasmic reticulum stress, neuroprotection and glial scar formation. Neural Regener. Res. 10:12 (2015), 1926–1927, 10.4103/1673-5374.169619 (PubMed PMID: 26889171 PubMed Central PMCID: PMC4730807).
57. [57] Barreda-Manso, M.A., Yanguas-Casas, N., Nieto-Sampedro, M., Romero-Ramirez, L., Salubrinal inhibits the expression of proteoglycans and favors neurite outgrowth from cortical neurons in vitro. Exp. Cell Res. 335:1 (2015), 82–90, 10.1016/j.yexcr.2015.04.002 (PubMed PMID: 25882497).
58. [58] Sokka, A.L., Putkonen, N., Mudo, G., Pryazhnikov, E., Reijonen, S., Khiroug, L., Belluardo, N., Lindholm, D., Korhonen, L., Endoplasmic reticulum stress inhibition protects against excitotoxic neuronal injury in the rat brain. J. Nneurosci. 27:4 (2007), 901–908, 10.1523/JNEUROSCI.4289-06.2007 (PubMed PMID: 17251432).
59. [59] Saxena, S., Cabuy, E., Caroni, P., A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. Nat. Neurosci. 12:5 (2009), 627–636, 10.1038/nn.2297 (PubMed PMID: 19330001).
60. [60] Axten, J.M., Medina, J.R., Feng, Y., Shu, A., Romeril, S.P., Grant, S.W., Li, W.H., Heerding, D.A., Minthorn, E., Mencken, T., Atkins, C., Liu, Q., Rabindran, S., Kumar, R., Hong, X., Goetz, A., Stanley, T., Taylor, J.D., Sigethy, S.D., Tomberlin, G.H., Hassell, A.M., Kahler, K.M., Shewchuk, L.M., Gampe, R.T., Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2, 3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2, 3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 55:16 (2012), 7193–7207, 10.1021/jm300713s (PubMed PMID: 22827572).
61. [61] Moreno, J.A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J.M., Ortori, C.A., Willis, A.E., Fischer, P.M., Barrett, D.A., Mallucci, G.R., Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci. Transl. Med., 5(206), 2013, 206ra138, 10.1126/scitranslmed.3006767 (PubMed PMID: 24107777).
62. [62] Axten, J.M., Romeril, S.P., Shu, A., Ralph, J., Medina, J.R., Feng, Y., Li, W.H., Grant, S.W., Heerding, D.A., Minthorn, E., Mencken, T., Gaul, N., Goetz, A., Stanley, T., Hassell, A.M., Gampe, R.T., Atkins, C., Kumar, R., Discovery of GSK2656157: an optimized PERK inhibitor selected for preclinical development. ACS Med. Chem. Lett. 4:10 (2013), 964–968, 10.1021/ml400228e (PubMed PMID: 24900593 PubMed Central PMCID: PMC4027568).
63. [63] Krishnamoorthy, J., Rajesh, K., Mirzajani, F., Kesoglidou, P., Papadakis, A.I., Koromilas, A.E., Evidence for eIF2alpha phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications. Cell Cycle 13:5 (2014), 801–806, 10.4161/cc.27726 (PubMed PMID: 24401334 PubMed Central PMCID: PMC3979916).
64. [64] Sidrauski, C., Acosta-Alvear, D., Khoutorsky, A., Vedantham, P., Hearn, B.R., Li, H., Gamache, K., Gallagher, C.M., Ang, K.K., Wilson, C., Okreglak, V., Ashkenazi, A., Hann, B., Nader, K., Arkin, M.R., Renslo, A.R., Sonenberg, N., Walter, P., Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife, 2, 2013, e00498, 10.7554/eLife.00498 (PubMed PMID: 23741617 PubMed Central PMCID: PMC3667625).
65. [65] Sidrauski, C., McGeachy, A.M., Ingolia, N.T., Walter, P., The small molecule ISRIB reverses the effects of eIF2alpha phosphorylation on translation and stress granule assembly. eLife, 4, 2015, 10.7554/eLife.05033 (PubMed PMID: 25719440 PubMed Central PMCID: PMC4341466).
66. [66] Smith, A.L., Andrews, K.L., Beckmann, H., Bellon, S.F., Beltran, P.J., Booker, S., Chen, H., Chung, Y.A., D'Angelo, N.D., Dao, J., Dellamaggiore, K.R., Jaeckel, P., Kendall, R., Labitzke, K., Long, A.M., Materna-Reichelt, S., Mitchell, P., Norman, M.H., Powers, D., Rose, M., Shaffer, P.L., Wu, M.M., Lipford, J.R., Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 58:3 (2015), 1426–1441, 10.1021/jm5017494 (PubMed PMID: 25587754).
67. [67] Norez, C., Vandebrouck, C., Antigny, F., Dannhoffer, L., Blondel, M., Becq, F., Guanabenz, an alpha2-selective adrenergic agonist, activates Ca2+-dependent chloride currents in cystic fibrosis human airway epithelial cells. Eur. J. Pharmacol. 592:1–3 (2008), 33–40, 10.1016/j.ejphar.2008.06.103 (PubMed PMID: 18640110).
68. [68] Tribouillard-Tanvier, D., Beringue, V., Desban, N., Gug, F., Bach, S., Voisset, C., Galons, H., Laude, H., Vilette, D., Blondel, M., Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. PLoS One, 3(4), 2008, e1981, 10.1371/journal.pone.0001981 (PubMed PMID: 18431471 PubMed Central PMCID: PMC2291559).
69. [69] Wang, L., Popko, B., Tixier, E., Roos, R.P., Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol. Dis. 71 (2014), 317–324, 10.1016/j.nbd.2014.08.010 (PubMed PMID: 25134731 PubMed Central PMCID: PMC4179984).
70. [70] Jiang, H.Q., Ren, M., Jiang, H.Z., Wang, J., Zhang, J., Yin, X., Wang, S.Y., Qi, Y., Wang, X.D., Feng, H.L., Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience 277 (2014), 132–138, 10.1016/j.neuroscience.2014.03.047 (PubMed PMID: 24699224).
71. [71] Das, I., Krzyzosiak, A., Schneider, K., Wrabetz, L., D'Antonio, M., Barry, N., Sigurdardottir, A., Bertolotti, A., Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348:6231 (2015), 239–242, 10.1126/science.aaa4484 (PubMed PMID: 25859045 PubMed Central PMCID: PMC4490275).
72. [72] Cross, B.C., Bond, P.J., Sadowski, P.G., Jha, B.K., Zak, J., Goodman, J.M., Silverman, R.H., Neubert, T.A., Baxendale, I.R., Ron, D., Harding, H.P., The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc. Natl. Acad. Sci. U. S. A. 109:15 (2012), E869–E878, 10.1073/pnas.1115623109 (PubMed PMID: 22315414 PubMed Central PMCID: PMC3326519).
73. [73] Papandreou, I., Denko, N.C., Olson, M., Van Melckebeke, H., Lust, S., Tam, A., Solow-Cordero, D.E., Bouley, D.M., Offner, F., Niwa, M., Koong, A.C., Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 117:4 (2011), 1311–1314, 10.1182/blood-2010-08-303099 (PubMed PMID: 21081713 PubMed Central PMCID: PMC3056474).
74. [74] Ghosh, R., Wang, L., Wang, E.S., Perera, B.G., Igbaria, A., Morita, S., Prado, K., Thamsen, M., Caswell, D., Macias, H., Weiberth, K.F., Gliedt, M.J., Alavi, M.V., Hari, S.B., Mitra, A.K., Bhhatarai, B., Schurer, S.C., Snapp, E.L., Gould, D.B., German, M.S., Backes, B.J., Maly, D.J., Oakes, S.A., Papa, F.R., Allosteric inhibition of the IRE1alpha RNase preserves cell viability and function during endoplasmic reticulum stress. Cell 158:3 (2014), 534–548, 10.1016/j.cell.2014.07.002 (PubMed PMID: 25018104 PubMed Central PMCID: PMC4244221).
75. [75] Li, S., Pu, X.P., Neuroprotective effect of kaempferol against a 1-methyl-4-phenyl-1, 2, 3 6-tetrahydropyridine-induced mouse model of Parkinson's disease. Biol. Pharm. Bull. 34:8 (2011), 1291–1296 (PubMed PMID: 21804220).
76. [76] Mu, X., He, G., Cheng, Y., Li, X., Xu, B., Du, G., Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol. Biochem. Behav. 92:4 (2009), 642–648, 10.1016/j.pbb.2009.03.008 (PubMed PMID: 19327378).
77. [77] Patil, S.P., Jain, P.D., Sancheti, J.S., Ghumatkar, P.J., Tambe, R., Sathaye, S., Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice. Neuropharmacology 86 (2014), 192–202, 10.1016/j.neuropharm.2014.07.012 (PubMed PMID: 25087727).
78. [78] Zhang, H., Nakajima, S., Kato, H., Gu, L., Yoshitomi, T., Nagai, K., Shinmori, H., Kokubo, S., Kitamura, M., Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues. Br. J. Pharmacol. 170:4 (2013), 822–834, 10.1111/bph.12306 (PubMed PMID: 23869584 PubMed Central PMCID: PMC3799596).
79. [79] Mimori, S., Okuma, Y., Kaneko, M., Kawada, K., Hosoi, T., Ozawa, K., Nomura, Y., Hamana, H., Protective effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress. Biol. Pharm. Bull. 35:1 (2012), 84–90 (PubMed PMID: 22223342).
80. [80] Vang, S., Longley, K., Steer, C.J., Low, W.C., The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob. Adv. Health Med. 3:3 (2014), 58–69, 10.7453/gahmj.2014.017 (PubMed PMID: 24891994 PubMed Central PMCID: PMC4030606).
81. [81] Elia, A.E., Lalli, S., Monsurro, M.R., Sagnelli, A., Taiello, A.C., Reggiori, B., LaBella, V., Tedeschi, G., Albanese, A., Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 23:1 (2016), 45–52, 10.1111/ene.12664 (PubMed PMID: 25664595).
82. [82] Peviani, M., Salvaneschi, E., Bontempi, L., Petese, A., Manzo, A., Rossi, D., Salmona, M., Collina, S., Bigini, P., Curti, D., Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol. Dis. 62 (2014), 218–232, 10.1016/j.nbd.2013.10.010 (PubMed PMID: 24141020).
83. [83] Kalmar, B., Lu, C.H., Greensmith, L., The role of heat shock proteins in Amyotrophic Lateral Sclerosis: the therapeutic potential of Arimoclomol. Pharmacol. Ther. 141:1 (2014), 40–54, 10.1016/j.pharmthera.2013.08.003 (PubMed PMID: 23978556).
84. [84] Paris, D., Ganey, N.J., Laporte, V., Patel, N.S., Beaulieu-Abdelahad, D., Bachmeier, C., March, A., Ait-Ghezala, G., Mullan, M.J., Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation, 7, 2010, 17, 10.1186/1742-2094-7-17 (PubMedPMID:20211007;PubMedCentralPMCID:PMC2841120).
85. [85] Kiaei, M., Kipiani, K., Petri, S., Chen, J., Calingasan, N.Y., Beal, M.F., Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2:5 (2005), 246–254, 10.1159/000090364 (PubMed PMID: 16909005).
86. [86] Ho, S.W., Tsui, Y.T., Wong, T.T., Cheung, S.K., Goggins, W.B., Yi, L.M., Cheng, K.K., Baum, L., Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in transgenic mouse models of frontotemporal lobar degeneration and Alzheimer's disease. Transl. Neurodegener., 2(1), 2013, 24, 10.1186/2047-9158-2-24 (PubMed PMID: 24344631 PubMed Central PMCID: PMC3878847).
87. [87] Ouyang, Y.B., Giffard, R.G., ER-Mitochondria crosstalk during cerebral ischemia: molecular chaperones and ER-Mitochondrial calcium transfer. Int. J. Cell Biol., 2012, 2012, 493934, 10.1155/2012/493934 (PubMedPMID:22577383;PubMedCentralPMCID:PMC3335182).
88. [88] Koch, G.L., The endoplasmic reticulum and calcium storage. BioEssays 12:11 (1990), 527–531, 10.1002/bies.950121105 (PubMed PMID: 2085319).
89. [89] Mekahli, D., Bultynck, G., Parys, J.B., De Smedt, H., Missiaen, L., Endoplasmic-reticulum calcium depletion and disease. Cold Spring Harb. Perspect. Biol., 3(6), 2011, 10.1101/cshperspect.a004317 (PMID: 21441595 PubMed; PubMed Central PMCID: PMC3098671).
90. [90] Li, M., Lester, H.A., Ion channel diseases of the central nervous system. CNS Drug Rev. 7:2 (2001), 214–240 (PubMed PMID: 11474425).
91. [91] Shirwany, N.A., Payette, D., Xie, J., Guo, Q., The amyloid beta ion channel hypothesis of Alzheimer's disease. Neuropsychiatr. Dis. Treat. 3:5 (2007), 597–612 (PubMed PMID: 19300589; PubMed Central PMCID: PMC2656296).
92. [92] Cataldi, M., The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases. Curr. Neuropharmacol. 11:3 (2013), 276–297, 10.2174/1570159X11311030004 (PubMed PMID: 24179464 PubMed Central PMCID: PMC3648780).
93. [93] Smith, R.G., Alexianu, M.E., Crawford, G., Nyormoi, O., Stefani, E., Appel, S.H., Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc. Natl. Acad. Sci. U. S. A. 91:8 (1994), 3393–3397 (PubMed PMID: 8159758 PubMed Central PMCID: PMC43583).
94. [94] Cheung, K.H., Shineman, D., Muller, M., Cardenas, C., Mei, L., Yang, J., Tomita, T., Iwatsubo, T., Lee, V.M., Foskett, J.K., Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58:6 (2008), 871–883, 10.1016/j.neuron.2008.04.015 (PubMed PMID: 18579078 PubMed Central PMCID: PMC2495086).
95. [95] Young, L.T., Kish, S.J., Li, P.P., Warsh, J.J., Decreased brain [3H]inositol 1, 4 5-trisphosphate binding in alzheimer's disease. Neurosci. Lett. 94:1–2 (1988), 198–202 (PubMed PMID: 2853852).
96. [96] Duncan, R.S., Goad, D.L., Grillo, M.A., Kaja, S., Payne, A.J., Koulen, P., Control of intracellular calcium signaling as a neuroprotective strategy. Molecules 15:3 (2010), 1168–1195, 10.3390/molecules15031168 (PubMed PMID: 20335972 PubMed Central PMCID: PMC2847496).
97. [97] Stutzmann, G.E., Caccamo, A., LaFerla, F.M., Parker, I., Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J. Neurosci. 24:2 (2004), 508–513, 10.1523/JNEUROSCI.4386-03.2004 (PubMed PMID: 14724250).
98. [98] Ferreiro, E., Resende, R., Costa, R., Oliveira, C.R., Pereira, C.M., An endoplasmic-reticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity. Neurobiol. Dis. 23:3 (2006), 669–678, 10.1016/j.nbd.2006.05.011 (PubMed PMID: 16844381).
99. [99] Kasri, N.N., Kocks, S.L., Verbert, L., Hebert, S.S., Callewaert, G., Parys, J.B., Missiaen, L., De Smedt, H., Up-regulation of inositol 1, 4 5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca2+ content in presenilin double knock-out cells. Cell Calcium 40:1 (2006), 41–51, 10.1016/j.ceca.2006.03.005 (PubMed PMID: 16675011).
100. [100] Chakroborty, S., Goussakov, I., Miller, M.B., Stutzmann, G.E., Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J. Neurosci. 29:30 (2009), 9458–9470, 10.1523/JNEUROSCI.2047–09.2009 (PubMed PMID: 19641109).
101. [101] Stutzmann, G.E., Smith, I., Caccamo, A., Oddo, S., Laferla, F.M., Parker, I., Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J. Neurosci. 26:19 (2006), 5180–5189, 10.1523/JNEUROSCI (PubMed PMID: 16687509).
102. [102] Kelliher, M., Fastbom, J., Cowburn, R.F., Bonkale, W., Ohm, T.G., Ravid, R., Sorrentino, V., O'Neill, C., Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 92:2 (1999), 499–513 (PubMed PMID: 10408600).
103. [103] Tang, T.S., Tu, H., Chan, E.Y., Maximov, A., Wang, Z., Wellington, C.L., Hayden, M.R., Bezprozvanny, I., Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39:2 (2003), 227–239 (PubMed PMID: 12873381; PubMed Central PMCID: PMC3220623).
104. [104] Tang, T.S., Guo, C., Wang, H., Chen, X., Bezprozvanny, I., Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J. Neurosci. 29:5 (2009), 1257–1266, 10.1523/JNEUROSCI.4411-08.2009 (PubMed PMID: 19193873; PubMed Central PMCID: PMC2768402).
105. [105] Chen, X., Wu, J., Lvovskaya, S., Herndon, E., Supnet, C., Bezprozvanny, I., Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol. Neurodegener., 6, 2011, 81, 10.1186/1750-1326-6-81 (PubMedPMID:22118545;PubMedCentralPMCID:PMC3235068).
106. [106] Chakroborty, S., Briggs, C., Miller, M.B., Goussakov, I., Schneider, C., Kim, J., Wicks, J., Richardson, J.C., Conklin, V., Cameransi, B.G., Stutzmann, G.E., Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. PLoS One, 7(12), 2012, e52056, 10.1371/journal.pone.0052056 (PubMed PMID: 23284867 PubMed Central PMCID: PMC3528716).
107. [107] Staats, K.A., Van Rillaer, M., Scheveneels, W., Verbesselt, R., Van Damme, P., Robberecht, W., Van Den Bosch, L., Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1(G(9)(3)A) mice. Neuroscience 220 (2012), 26–31, 10.1016/j.neuroscience.2012.06.050 (PubMed PMID: 22750242).
108. [108] Dziadek, M.A., Johnstone, L.S., Biochemical properties and cellular localisation of STIM proteins. Cell Calcium 42:2 (2007), 123–132, 10.1016/j.ceca.2007.02.006 (PubMed PMID: 17382385).
109. [109] Bezprozvanny, I.B., Calcium signaling and neurodegeneration. Acta Nat. 2:1 (2010), 72–82 (PubMed PMID: 22649630; PubMed Central PMCID: PMC3347543).
110. [110] Leissring, M.A., Akbari, Y., Fanger, C.M., Cahalan, M.D., Mattson, M.P., LaFerla, F.M., Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J. Cell Biol. 149:4 (2000), 793–798 (PubMed PMID: 10811821; PubMed Central PMCID: PMC2174559).
111. [111] Yoo, A.S., Cheng, I., Chung, S., Grenfell, T.Z., Lee, H., Pack-Chung, E., Handler, M., Shen, J., Xia, W., Tesco, G., Saunders, A.J., Ding, K., Frosch, M.P., Tanzi, R.E., Kim, T.W., Presenilin-mediated modulation of capacitative calcium entry. Neuron 27:3 (2000), 561–572 (PubMed PMID: 11055438).
112. [112] Kawamata, H., Ng, S.K., Diaz, N., Burstein, S., Morel, L., Osgood, A., Sider, B., Higashimori, H., Haydon, P.G., Manfredi, G., Yang, Y., Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis. J. Neurosci. 34:6 (2014), 2331–2348, 10.1523/JNEUROSCI (PubMed PMID: 24501372 PubMed Central PMCID: PMC3913875).
113. [113] Wu, J., Shih, H.P., Vigont, V., Hrdlicka, L., Diggins, L., Singh, C., Mahoney, M., Chesworth, R., Shapiro, G., Zimina, O., Chen, X., Wu, Q., Glushankova, L., Ahlijanian, M., Koenig, G., Mozhayeva, G.N., Kaznacheyeva, E., Bezprozvanny, I., Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chem. Biol. 18:6 (2011), 777–793, 10.1016/j.chembiol.2011.04.012 (PubMed PMID: 21700213 PubMed Central PMCID: PMC3124661).
114. [114] Czeredys, M., Gruszczynska-Biegala, J., Schacht, T., Methner, A., Kuznicki, J., Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington's disease. Front. Mol. Neurosci., 6, 2013, 42, 10.3389/fnmol.2013.00042 (PubMedPMID:24324398;PubMedCentralPMCID:PMC3838962).
115. [115] Rowland, A.A., Voeltz, G.K., Endoplasmic reticulum-mitochondria contacts: function of the junction. Nat. Rev. Mol. Cell Biol. 13:10 (2012), 607–625, 10.1038/nrm3440 (PubMed PMID: 22992592).
116. [116] Gupta, S., Read, D.E., Deepti, A., Cawley, K., Gupta, A., Oommen, D., Verfaillie, T., Matus, S., Smith, M.A., Mott, J.L., Agostinis, P., Hetz, C., Samali, A., Perk-dependent repression of miR-106b-25 cluster is required for ER stress-induced apoptosis. Cell Death Dis., 3, 2012, e333, 10.1038/cddis.2012.74 (PubMed PMID: 22739985 PubMed Central PMCID: PMC3388242).
117. [117] Verfaillie, T., Rubio, N., Garg, A.D., Bultynck, G., Rizzuto, R., Decuypere, J.P., Piette, J., Linehan, C., Gupta, S., Samali, A., Agostinis, P., PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 19:11 (2012), 1880–1891, 10.1038/cdd.2012.74 (PubMed PMID: 22705852 PubMed Central PMCID: PMC3469056).
118. [118] Poston, C.N., Duong, E., Cao, Y., Bazemore-Walker, C.R., Proteomic analysis of lipid raft-enriched membranes isolated from internal organelles. Biochem. Biophys. Res. Commun. 415:2 (2011), 355–360, 10.1016/j.bbrc.2011.10.072 (PubMed PMID: 22037461 PubMed Central PMCID: PMC3253365).
119. [119] Hayashi, T., Su, T.P., Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2 +) signaling and cell survival. Cell 131:3 (2007), 596–610, 10.1016/j.cell.2007.08.036 (PubMed PMID: 17981125).
120. [120] Munoz, J.P., Ivanova, S., Sanchez-Wandelmer, J., Martinez-Cristobal, P., Noguera, E., Sancho, A., Diaz-Ramos, A., Hernandez-Alvarez, M.I., Sebastian, D., Mauvezin, C., Palacin, M., Zorzano, A., Mfn2 modulates the UPR and mitochondrial function via repression of PERK. EMBO J. 32:17 (2013), 2348–2361, 10.1038/emboj.2013.168 (PubMed PMID: 23921556 PubMed Central PMCID: PMC3770335).
121. [121] Deniaud, A., Sharaf el dein, O., Maillier, E., Poncet, D., Kroemer, G., Lemaire, C., Brenner, C., Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27:3 (2008), 285–299, 10.1038/sj.onc.1210638 (PubMed PMID: 17700538).
122. [122] Pinton, P., Giorgi, C., Siviero, R., Zecchini, E., Rizzuto, R., Calcium and apoptosis ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 27:50 (2008), 6407–6418, 10.1038/onc.2008.308 (PubMed PMID: 18955969; PubMed Central PMCID: PMC2844952).
123. [123] Raturi, A., Simmen, T., Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM). Biochim. Biophys. Acta 1833:1 (2013), 213–224, 10.1016/j.bbamcr.2012.04.013 (PubMed PMID: 22575682).
124. [124] Area-Gomez, E., Del Carmen Lara Castillo, M., Tambini, M.D., Guardia-Laguarta, C., de Groof, A.J., Madra, M., Ikenouchi, J., Umeda, M., Bird, T.D., Sturley, S.L., Schon, E.A., Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31:21 (2012), 4106–4123, 10.1038/emboj.2012.202 (PubMed PMID: 22892566; PubMed Central PMCID: PMC3492725).
125. [125] Hedskog, L., Pinho, C.M., Filadi, R., Ronnback, A., Hertwig, L., Wiehager, B., Larssen, P., Gellhaar, S., Sandebring, A., Westerlund, M., Graff, C., Winblad, B., Galter, D., Behbahani, H., Pizzo, P., Glaser, E., Ankarcrona, M., Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. Proc. Natl. Acad. Sci. U. S. A. 110:19 (2013), 7916–7921, 10.1073/pnas.1300677110 (PubMed PMID: 23620518 PubMed Central PMCID: PMC3651455).
126. [126] Schreiner, B., Hedskog, L., Wiehager, B., Ankarcrona, M., Amyloid-beta peptides are generated in mitochondria-associated endoplasmic reticulum membranes. J. Alzheimer's Dis. 43:2 (2015), 369–374, 10.3233/JAD-132543 (PubMed PMID: 25096627).
127. [127] Stoica, R., De Vos, K.J., Paillusson, S., Mueller, S., Sancho, R.M., Lau, K.F., Vizcay-Barrena, G., Lin, W.L., Xu, Y.F., Lewis, J., Dickson, D.W., Petrucelli, L., Mitchell, J.C., Shaw, C.E., Miller, C.C., ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat. Commun., 5, 2014, 3996, 10.1038/ncomms4996 (PubMedPMID:24893131;PubMedCentralPMCID:PMC4046113).
128. [128] Ottolini, D., Cali, T., Negro, A., Brini, M., The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. Hum. Mol. Genet. 22:11 (2013), 2152–2168, 10.1093/hmg/ddt068 (PubMed PMID: 23418303).
129. [129] Kornfeld, O.S., Hwang, S., Disatnik, M.-H., Chen, C.-H., Qvit, N., Mochly-Rosen, D., Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases. Circ. Res. 116:11 (2015), 1783–1799, 10.1161/circresaha.116.305432 (PubMed PMID: 25999419).
130. [130] Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 287:4 (2004), C817–C833, 10.1152/ajpcell.00139.2004 (PubMed PMID: 15355853).
131. [131] Mink, J.W., Blumenschine, R.J., Adams, D.B., Ratio of central nervous-system to body metabolism in vertebrates – its constancy and functional basis. Am. J. Physiol., 241(3), 1981 (R203-R12. PubMed PMID: WOS:A1981MG81500084).
132. [132] Llorente-Folch, I., Rueda, C.B., Pardo, B., Szabadkai, G., Duchen, M.R., Satrustegui, J., The regulation of neuronal mitochondrial metabolism by calcium. J. Physiol. (London) 593:16 (2015), 3447–3462, 10.1113/Jp270254 (PubMed PMID: WOS: 000359733900006).
133. [133] Almeida, A., Almeida, J., Bolanos, J.P., Moncada, S., Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc. Natl. Acad. Sci. U. S. A. 98:26 (2001), 15294–15299, 10.1073/pnas.261560998 (PubMed PMID: WOS: 000172848800099).
134. [134] Herrero-Mendez, A., Almeida, A., Fernandez, E., Maestre, C., Moncada, S., Bolanos, J.P., The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1. Nat. Cell Biol., 11(6), 2009, 10.1038/ncb1881 747–U105, PubMed PMID: WOS: 000266503700020.
135. [135] Potter, V.R., Siekevitz, P., Simonson, H.C., Latent adenosinetriphosphatase activity in resting rat liver mitochondria. J. Biol. Chem. 205:2 (1953), 893–908 (PubMed PMID: 13129268).
136. [136] Chance, B., The energy-Linked reaction of calcium with mitochondria. J. Biol. Chem. 240 (1965), 2729–2748 (PubMed PMID: 14304892).
137. [137] Reed, K.C., Bygrave, F.L., Inhibition of mitochondrial calcium-Transport by lanthanides and ruthenium red. Biochem. J. 140:2 (1974), 143–155 (PubMed PMID: WOS:A1974T267800003).
138. [138] Glancy, B., Willis, W.T., Chess, D.J., Balaban, R.S., Effect of calcium on the oxidative phosphorylation cascade in skeletal muscle mitochondria. Biochemistry 52:16 (2013), 2793–2809, 10.1021/bi3015983 (PubMed PMID: WOS: 000318143700009).
139. [139] Panov, A.V., Scaduto, R.C., Influence of calcium on nadh and succinate oxidation by rat-heart submitochondrial particles. Arch. Biochem. Biophys. 316:2 (1995), 815–820, 10.1006/abbi.1995.1109 (PubMed PMID: WOS:A1995QH02900022).
140. [140] Bender, E., Kadenbach, B., The allosteric ATP-inhibition of cytochrome c oxidase activity is reversibly switched on by cAMP-dependent phosphorylation. FEBS Lett. 466:1 (2000), 130–134, 10.1016/S0014-5793(99)01773-1 (PubMed PMID: WOS:000085022000027).
141. [141] Tahara, E.B., Navarete, F.D., Kowaltowski, A.J., Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic. Biol. Med. 46:9 (2009), 1283–1297, 10.1016/j.freeradbiomed.2009.02.008 Eub 2009/02/28. S0891-5849(09)00081-1 [ii]. PubMed PMID: 19245829.
142. [142] Sohal, R.S., Allen, R.G., Relationship between metabolic rate, free radicals, differentiation and aging: a unified theory. Basic Life Sci. 35 (1985), 75–104 (PubMed PMID: MEDLINE:4062824).
143. [143] Feissner, R.F., Skalska, J., Gaum, W.E., Sheu, S.S., Crosstalk signaling between mitochondrial Ca2+ and ROS. Front. Biosci. (Landmark) 14 (2009), 1197–1218, 10.2741/3303 (PubMed PMID: WOS: 000262352400076).
144. [144] Sousa, S.C., Maciel, E.N., Vercesi, A.E., Castilho, R.F., Ca2+-induced oxidative stress in brain mitochondria treated with the respiratory chain inhibitor rotenone. FEBS Lett. 543:1–3 (2003), 179–183, 10.1016/s0014-5793(03)00421-6 (PubMed PMID: WOS:000183121500036).
145. [145] Harman, D., Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11 (1956), 298–300.
146. [146] Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:7113 (2006), 787–795, 10.1038/nature05292 (PubMed PMID: 17051205).
147. [147] Barnham, K.J., Masters, C.L., Bush, A.I., Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 3:3 (2004), 205–214, 10.1038/nrd1330 (PubMed PMID: 15031734).
148. [148] Emerit, J., Edeas, M., Bricaire, F., Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58:1 (2004), 39–46 (PubMed PMID: 14739060).
149. [149] Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., Yankner, B.A., Gene regulation and DNA damage in the ageing human brain. Nature 429:6994 (2004), 883–891, 10.1038/nature02661 (PubMed PMID: 15190254).
150. [150] Lebovitz, R.M., Zhang, H., Vogel, H., Cartwright, J. Jr., Dionne, L., Lu, N., Huang, S., Matzuk, M.M., Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:18 (1996), 9782–9787 (PubMed PMID: 8790408 PubMed Central PMCID: PMCPMC38506).
151. [151] Galasko, D.R., Peskind, E., Clark, C.M., Quinn, J.F., Ringman, J.M., Jicha, G.A., Cotman, C., Cottrell, B., Montine, T.J., Thomas, R.G., Aisen, P., Study, A.D.C., Antioxidants for alzheimer disease a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch. Neurol. (Chicago) 69:7 (2012), 836–841, 10.1001/archneurol.2012.85 (PubMed PMID: WOS:000306189400005).
152. [152] Parkinson Study Group QEI, Beal, M.F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W.R., Haas, R., Juncos, J.L., Nutt, J.G., Voss, T.S., Ravina, B., Shults, C.M., Helles, K., Snively, V., Lew, M.F., Griebner, B., Watts, A., Gao, S., Pourcher, E., Bond, L., Kompoliti, K., Agarwal, P., Sia, C., Jog, M., Cole, L., Sultana, M., Kurlan, R., Richard, I., Deeley, C., Waters, C.H., Figueroa, A., Arkun, A., Brodsky, M., Ondo, W.G., Hunter, C.B., Jimenez-Shahed, J., Palao, A., Miyasaki, J.M., So, J., Tetrud, J., Reys, L., Smith, K., Singer, C., Blenke, A., Russell, D.S., Cotto, C., Friedman, J.H., Lannon, M., Zhang, L., Drasby, E., Kumar, R., Subramanian, T., Ford, D.S., Grimes, D.A., Cote, D., Conway, J., Siderowf, A.D., Evatt, M.L., Sommerfeld, B., Lieberman, A.N., Okun, M.S., Rodriguez, R.L., Merritt, S., Swartz, C.L., Martin, W.R., King, P., Stover, N., Guthrie, S., Watts, R.L., Ahmed, A., Fernandez, H.H., Winters, A., Mari, Z., Dawson, T.M., Dunlop, B., Feigin, A.S., Shannon, B., Nirenberg, M.J., Ogg, M., Ellias, S.A., Thomas, C.A., Frei, K., Bodis-Wollner, I., Glazman, S., Mayer, T., Hauser, R.A., Pahwa, R., Langhammer, A., Ranawaya, R., Derwent, L., Sethi, K.D., Farrow, B., Prakash, R., Litvan, I., Robinson, A., Sahay, A., Gartner, M., Hinson, V.K., Markind, S., Pelikan, M., Perlmutter, J.S., Hartlein, J., Molho, E., Evans, S., Adler, C.H., Duffy, A., Lind, M., Elmer, L., Davis, K., Spears, J., Wilson, S., Leehey, M.A., Hermanowicz, N., Niswonger, S., Shill, H.A., Obradov, S., Rajput, A., Cowper, M., Lessig, S., Song, D., Fontaine, D., Zadikoff, C., Williams, K., Blindauer, K.A., Bergholte, J., Propsom, C.S., Stacy, M.A., Field, J., Mihaila, D., Chilton, M., Uc, E.Y., Sieren, J., Simon, D.K., Kraics, L., Silver, A., Boyd, J.T., Hamill, R.W., Ingvoldstad, C., Young, J., Thomas, K., Kostyk, S.K., Wojcieszek, J., Pfeiffer, R.F., Panisset, M., Beland, M., Reich, S.G., Cines, M., Zappala, N., Rivest, J., Zweig, R., Lumina, L.P., Hilliard, C.L., Grill, S., Kellermann, M., Tuite, P., Rolandelli, S., Kang, U.J., Young, J., Rao, J., Cook, M.M., Severt, L., Boyar, K., A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 71:5 (2014), 543–552, 10.1001/jamaneurol.2014.131 (PubMed PMID: 24664227).
153. [153] Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., Hamada, C., Kondo, K., Yoneoka, T., Akimoto, M., Yoshino, H., Edaravone, A.L.S.S.G., Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler. Frontotemporal Degener. 15:7-8 (2014), 610–617, 10.3109/21678421.2014.959024 (PubMed PMID: 25286015; PubMed Central PMCID: PMCPMC4266079).
154. [154] Kim, S., Joe, Y., Jeong, S.O., Zheng, M., Back, S.H., Park, S.W., Ryter, S.W., Chung, H.T., Endoplasmic reticulum stress is sufficient for the induction of IL-1 beta production via activation of the NF-kappa B and inflammasome pathways. Innate Immun. 20:8 (2014), 799–815, 10.1177/1753425913508593 (PubMed PMID: WOS:000343807400002).
155. [155] Sena, L.A., Chandel, N.S., Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48:2 (2012), 158–167, 10.1016/j.molcel.2012.09.025 (PubMed PMID: 23102266 PubMed Central PMCID: PMCPMC3484374).
156. [156] Group HIotHS, European Huntington's Disease N. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol. 70:1 (2013), 25–33, 10.1001/2013.jamaneurol.382 (PubMed PMID: 23108692).
157. [157] Doody, R.S., Gavrilova, S.I., Sano, M., Thomas, R.G., Aisen, P.S., Bachurin, S.O., Seely, L., Hung D, dimebon i. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372:9634 (2008), 207–215, 10.1016/S0140-6736(08)61074-0 (PubMed PMID: 18640457).
158. [158] Jones, R.W., Dimebon disappointment. Alzheimers Res. Ther., 2(5), 2010, 25, 10.1186/alzrt49 (PubMed PMID: 20836898 PubMed Central PMCID: PMCPMC2983434).
159. [159] Szeto, H.H., Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J. 8 (2006), E521–E531, 10.1208/aapsj080362 (PubMed PMID: 17025271).
160. [160] Birk, A.V., Chao, W.M., Bracken, C., Warren, J.D., Szeto, H.H., Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br. J. Pharmacol. 171 (2014), 2017–2028, 10.1111/bph.12468 (PubMed PMID: 24134698).
161. [161] Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N.Y., Szeto, H.H., Beal, M.F., Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 98:4 (2006), 1141–1148, 10.1111/j.1471-4159.2006.04018.x (PubMed PMID: 16895581).
162. [162] Yang, L., Zhao, K., Calingasan, N.Y., Luo, G., Szeto, H.H., Beal, M.F., Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1, 2, 3 6-tetrahydropyridine neurotoxicity. Antioxid. Redox Signal. 11:9 (2009), 2095–2104, 10.1089/ARS.2009.2445 (PubMed PMID: 19203217 PubMed Central PMCID: PMCPMC2819801).
163. [163] Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., Kanthasamy, A.G., Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta 1842:8 (2014), 1282–1294, 10.1016/j.bbadis.2013.09.007 (PubMed PMID: 24060637 PubMed Central PMCID: PMCPMC3961561).
164. [164] Snow, B.J., Rolfe, F.L., Lockhart, M.M., Frampton, C.M., O'Sullivan, J.D., Fung, V., Smith, R.A., Murphy, M.P., Taylor, K.M., A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25:11 (2010), 1670–1674, 10.1002/mds.23148 (PubMed PMID: 20568096).
165. [165] Sheng, Z.H., Cai, Q., Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat. Rev. Neurosci. 13:2 (2012), 77–93, 10.1038/nrn3156 (PubMed PMID: 22218207).
166. [166] Billups, B., Forsythe, I.D., Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J. Neurosc. 22:14 (2002), 5840–5847 (doi: 20026597. PubMed PMID: 12122046).
167. [167] Clayton, D.A., Replication of animal mitochondrial DNA. Cell 28:4 (1982), 693–705 (Epub 1982/04/01. PubMed PMID: 6178513).
168. [168] Youle, R.J., Van Der Bliek, A.M., Mitochondrial fission, fusion, and stress. Science 337:6098 (2012), 1062–1065.
169. [169] Otsuga, D., Keegan, B.R., Brisch, E., Thatcher, J.W., Hermann, G.J., Bleazard, W., Shaw, J.M., The dynamin-related GTPase, dnm1p, controls mitochondrial morphology in yeast. J. Cell Biol. 143:2 (1998), 333–349, 10.1083/jcb.143.2.333 (PubMed PMID: 9786946).
170. [170] Smirnova, E., Shurland, D.-L., Ryazantsev, S.N., van der Bliek, A.M.A., Human dynamin-related protein controls the distribution of mitochondria. J. Cell Biol. 143:2 (1998), 351–358, 10.1083/jcb.143.2.351 (PubMed PMID: 9786947).
171. [171] Chen, H., McCaffery, J.M., Chan, D.C., Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 130:3 (2007), 548–562 (PubMed PMID: 17693261).
172. [172] Chen, H., Chan, D.C., Physiological functions of mitochondrial fusion. Ann. N. Y. Acad. Sci. 1201 (2010), 21–25, 10.1111/j.1749-6632.2010.05615.x (Epub 2010/07/24. PubMed PMID: 20649534).
173. [173] Figueroa-Romero, C., Iñiguez-Lluhí, J.A., Stadler, J., Chang, C.-R., Arnoult, D., Keller, P.J., Hong, Y., Blackstone, C., Feldman, E.L., SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. FASEB J. 23:11 (2009), 3917–3927 (PubMed PMID: 19638400).
174. [174] Braschi, E., Zunino, R., McBride, H.M., MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Rep. 10:7 (2009), 748–754, 10.1038/embor.2009.86 (PubMed PMID: WOS: 000267599700018).
175. [175] Prudent, J., Zunino, R., Sugiura, A., Mattie, S., Shore, G.C., McBride, H.M., MAPL SUMOylation of drp1 stabilizes an ER/Mitochondrial platform required for cell death. Mol. Cell 59:6 (2015), 941–955, 10.1016/j.molcel.2015.08.001 (PubMed PMID: WOS:000365166500008).
176. [176] Karbowski, M., Neutzner, A., Youle, R.J., The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J. Cell Biol. 178:1 (2007), 71–84 (PubMed PMID: 17606867).
177. [177] Jahani-Asl, A., Slack, R.S., The phosphorylation state of Drp1 determines cell fate. EMBO Rep. 8:10 (2007), 912–913, 10.1038/sj.embor.7401077 (PubMed PMID: 17906671 PubMed Central PMCID: PMCPMC2002565).
178. [178] Cribbs, J.T., Strack, S., Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. 8 (2007), 939–944, 10.1038/sj.embor.7401062 (PubMed PMID: 17721437).
179. [179] Chang, C.R., Blackstone, C., Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J. Biol. Chem. 282:30 (2007), 21583–21587, 10.1074/jbc.C700083200 (PubMed PMID: WOS:000248196800003).
180. [180] Cereghetti, G.M., Stangherlin, A., Martins de brito O, chang CR, blackstone C, bernardi P, scorrano L. dephosphorylation by calcineurin regulates translocation of drp1 to mitochondria. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 15803–15808, 10.1073/pnas.0808249105 (PubMed PMID: 18838687).
181. [181] Ishihara, N., Nomura, M., Jofuku, A., Kato, H., Suzuki, S.O., Masuda, K., Otera, H., Nakanishi, Y., Nonaka, I., Goto, Y.I., Taguchi, N., Morinaga, H., Maeda, M., Takayanagi, R., Yokota, S., Mihara, K., Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell Biol., 11(8), 2009, 10.1038/ncb1907 958–U114, PubMed PMID: WOS 000268593200009.
182. [182] Wakabayashi, J., Zhang, Z.Y., Wakabayashi, N., Tamura, Y., Fukaya, M., Kensler, T.W., Iijima, M., Sesaki, H., The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J. Cell Biol. 186:6 (2009), 805–816, 10.1083/jcb.200903065 (PubMed PMID: WOS 000269960800006).
183. [183] Jeyaraju, D.V., Cisbani, G., Pellegrini, L., Calcium regulation of mitochondria motility and morphology. Biochim. Biophys. Acta 1787 (2009), 1363–1373.
184. [184] Shalizi, A., Gaudilliere, B., Yuan, Z., Stegmuller, J., Shirogane, T., Ge, Q., Tan, Y., Schulman, B., Harper, J.W., Bonni, A., A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311:5763 (2006), 1012–1017, 10.1126/science.1122513 (PubMed PMID: 16484498).
185. [185] Loriol, C., Casse, F., Khayachi, A., Poupon, G., Chafai, M., Deval, E., Gwizdek, C., Martin S: mGlu5 receptors regulate synaptic sumoylation via a transient PKC-dependent diffusional trapping of Ubc9 into spines. Nat. Commun., 5, 2014, 5113, 10.1038/ncomms6113 (PubMedPMID:25311713).
186. [186] Wasiak, S., Zunino, R., McBride, H.M., Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J. Cell Biol. 177:3 (2007), 439–450, 10.1083/jcb.200610042 (PubMed PMID: 17470634 PubMed Central PMCID: PMCPMC2064824).
187. [187] Tan, A.R., Cai, A.Y., Deheshi, S., Rintoul, G.L., Elevated intracellular calcium causes distinct mitochondrial remodelling and calcineurin-dependent fission in astrocytes. Cell Calcium 49:2 (2011), 108–114, 10.1016/j.ceca.2010.12.002 (PubMed PMID: 21216007).
188. [188] Deheshi, S., Dabiri, B., Fan, S., Tsang, M., Rintoul, G.L., Changes in mitochondrial morphology induced by calcium or rotenone in primary astrocytes occur predominantly through ros-mediated remodeling. J. Neurochem. 133:5 (2015), 684–699, 10.1111/jnc.13090 (PubMed PMID: WOS 000353570500007).
189. [189] Hroudova, J., Singh, N., Fisar, Z., Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. BioMed Res. Int., 2014, 2014, 175062, 10.1155/2014/175062 (Epub 2014/06/06PubMed. PMID:24900954;PubMedCentralPMCID:PMCPmc4036420).
190. [190] Johri, A., Beal, M.F., Mitochondrial dysfunction in neurodegenerative diseases. J. Pharmacol. Exp. Ther. 342:3 (2012), 619–630, 10.1124/jpet.112.192138 (PubMed PMID: 22700435 PubMed Central PMCID: PMC3422529).
191. [191] Itoh, K., Nakamura, K., Iijima, M., Sesaki, H., Mitochondrial dynamics in neurodegeneration. Trends Cell Biol. 23:2 (2013), 64–71, 10.1016/j.tcb.2012.10.006 (Epub 2012/11/20. PubMed PMID: 23159640 PubMed Central PMCID: PMC3558617).
192. [192] Cronin-Furman, E.N., Borland, M.K., Bergquist, K.E., Bennett, J.P. Jr., Trimmer, P.A., Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol. Neurodegener., 8, 2013, 6, 10.1186/1750-1326-8-6 (PubMedPMID:23351342; PubMedCentralPMCID:PMCPMC3577453).
193. [193] Reddy, P.H., Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov. Today 19:7 (2014), 951–955, 10.1016/j.drudis.2014.03.020 (PubMed PMID: 24681059 PubMed Central PMCID: PMCPMC4191657).
194. [194] Shirendeb, U., Reddy, A.P., Manczak, M., Calkins, M.J., Mao, P., Tagle, D.A., Reddy, P.H., Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 20:7 (2011), 1438–1455, 10.1093/hmg/ddr024 (PubMed PMID: 21257639 PubMed Central PMCID: PMCPMC3049363).
195. [195] Brustovetsky, N., Mutant huntingtin and elusive defects in oxidative metabolism and mitochondrial calcium handling. Mol. Neurobiol., 2015, 10.1007/s12035-015-9188-0 (PubMed PMID 25941077).
196. [196] Cassidy-Stone, A., Chipuk, J.E., Ingerman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M.J., Shaw, J.T., Hinshaw, J.E., Green, D.R., Nunnari, J., Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 14 (2008), 193–204, 10.1016/j.devcel.2007.11.019 (PubMed PMID: 18267088).
197. [197] Cui, M., Tang, X., Christian, W.V., Yoon, Y., Tieu, K., Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. The Journal of biological chemistry. 285:15 (2010), 11740–11752, 10.1074/jbc.M109.066662 (PubMed PMID: 20164189 PubMed Central PMCID: PMCPMC2857048).
198. [198] Twaroski, D.M., Yan, Y., Zaja, I., Clark, E., Bosnjak, Z.J., Bai, X., Altered mitochondrial dynamics contributes to propofol-induced cell death in human stem cell-derived neurons. Anesthesiology 123:5 (2015), 1067–1083, 10.1097/ALN.0000000000000857 (PubMed PMID: 26352374 PubMed Central PMCID: PMCPMC4632973).
199. [199] Akita, M., Suzuki-Karasaki, M., Fujiwara, K., Nakagawa, C., Soma, M., Yoshida, Y., Ochiai, T., Tokuhashi, Y., Suzuki-Karasaki, Y., Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis. Int. J. Oncol. 45:5 (2014), 1901–1912.
200. [200] Wang, J., Hansen, K., Edwards, R., Van Houten, B., Qian, W., Mitochondrial division inhibitor 1 (mdivi-1) enhances death receptor-mediated apoptosis in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 456:1 (2015), 7–12.
201. [201] Salabei, J.K., Hill, B.G., Mitochondrial fission induced by platelet-derived growth factor regulates vascular smooth muscle cell bioenergetics and cell proliferation. Redox Biol. 1:1 (2013), 542–551.
202. [202] Kim, B., Kim, J.-S., Yoon, Y., Santiago, M.C., Brown, M.D., Park, J.-Y., Inhibition of Drp1-dependent mitochondrial division impairs myogenic differentiation. Am. J. Physiol. 305:8 (2013), R927–R938.
203. [203] Ji-Yeong, Y., Sung-Hun, M., Hyo-Jin, P., Jin-Woo, K., Yong-Hee, L., Soo-Yong, P., Pil-Soo JEONG, H.P., Dong-Seok, L., Sun-Uk, K., Kyu-Tae Chang, D.-B.K., Mdivi-1, mitochondrial fission inhibitor, impairs developmental competence and mitochondrial function of embryos and cells in pigs. J. Reprod. Dev., 61(2), 2015, 81.
204. [204] Qi, X., Qvit, N., Su, Y.-C., Mochly-Rosen, D., A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci. 126 (2013), 789–802 (PubMed PMID: 23239023).
205. [205] Guo, X., Disatnik, M.-H., Monbureau, M., Shamloo, M., Mochly-Rosen, D., Qi, X., Inhibition of mitochondrial fragmentation diminishes Huntington disease—associated neurodegeneration. J Clin. Invest., 2013, 123, 10.1172/JCI70911DS1 (PubMed PMID: 24231356).
206. [206] Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov. Today 20:1 (2015), 122–128, 10.1016/j.drudis.2014.10.003 (PubMed PMID: 25450771).
207. [207] Corzo, G., Escoubas, P., Pharmacologically active spider peptide toxins. Cell. Mol. Life Sci. 60:11 (2003), 2409–2426, 10.1007/s00018-003-3108-6 (PubMed PMID: 14625686).
208. [208] Qvit, N., Kornfeld, O.S., Development of a backbone cyclic peptide library as potential antiparasitic therapeutics using microwave irradiation. J. Vis. Exp., 107, 2016, 10.3791/53589.
209. [209] Cai, Q., Sheng, Z.H., Moving or stopping mitochondria: miro as a traffic cop by sensing calcium. Neuron 61:4 (2009), 493–496, 10.1016/j.neuron.2009.02.003 (PubMed PMID: 19249268).
210. [210] van Spronsen, M., Mikhaylova, M., Lipka, J., Schlager, M.A., van den Heuvel, D.J., Kuijpers, M., Wulf, P.S., Keijzer, N., Demmers, J., Kapitein, L.C., Jaarsma, D., Gerritsen, H.C., Akhmanova, A., Hoogenraad, C.C., TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and dendrites. Neuron 77:3 (2013), 485–502, 10.1016/j.neuron.2012.11.027 (PubMed PMID: 23395375).
211. [211] Macaskill, A.F., Rinholm, J.E., Twelvetrees, A.E., Arancibia-Carcamo, I.L., Muir, J., Fransson, A., Aspenstrom, P., Attwell, D., Kittler, J.T., Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondria at synapses. Neuron 61:4 (2009), 541–555, 10.1016/j.neuron.2009.01.030 (PubMed PMID: 19249275 PubMed Central PMCID: PMCPMC2670979).
212. [212] Wang, X., Schwarz, T.L., The mechanism of Ca2+ −dependent regulation of kinesin-mediated mitochondrial motility. Cell 136:1 (2009), 163–174, 10.1016/j.cell.2008.11.046 (PubMed PMID: 19135897 PubMed Central PMCID: PMCPMC2768392).
213. [213] Saotome, M., Safiulina, D., Szabadkai, G., Das, S., Fransson, A., Aspenstrom, P., Rizzuto, R., Hajnoczky, G., Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proc. Natl. Acad. Sci. U.S.A. 105:52 (2008), 20728–20733, 10.1073/pnas.0808953105 (PubMed PMID: 19098100; PubMed Central PMCID: PMCPMC2634948.).
214. [214] Rasola, A., Bernardi, P., The mitochondrial permeability transition pore and its adaptive responses in tumor cells. Cell Calcium 56:6 (2014), 437–445, 10.1016/j.ceca.2014.10.003 (PubMed PMID: 25454774 PubMed Central PMCID: PMCPMC4274314).
215. [215] Bernardi, P., The mitochondrial permeability transition pore: a mystery solved?. Front. Physiol. 4 (2013), 1–12, 10.3389/fphys.2013.00095 (PubMed PMID: 23675351).
216. [216] Rasola, A., Bernardi, P., Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis. Cell Calcium 50:3 (2011), 222–233, 10.1016/j.ceca.2011.04.007 (PubMed PMID: WOS:000295744800003).
217. [217] Alam, M.R., Baetz, D., Ovize, M., Cyclophilin D and myocardial ischemia?reperfusion injury: a fresh perspective. J. Mol. Cell. Cardiol. 78 (2015), 80–89, 10.1016/j.yjmcc.2014.09.026.
218. [218] Liu, J., Farmer, J.D., Lane, W.S., Friedman, J., Weissman, I., Schreiber, S.L., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991), 807–815, 10.1016/0092-8674(91)90124-H (PubMed PMID: 1715244).
219. [219] Sweeney, Z.K., Fu, J., Wiedmann, B., From chemical tools to clinical medicines: non-immunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds. J. Med. Chem. 57 (2014), 7145–7159, 10.1021/jm500223x (PubMed PMID: 24831536).
220. [220] Azzolin, L., Antolini, N., Calderan, A., Ruzza, P., Sciacovelli, M., Marin, O., Mammi, S., Bernardi, P., Rasola, A., Antamanide, a derivative of Amanita phalloides, is a novel inhibitor of the mitochondrial permeability transition pore. PLoS One, 6(1), 2011, e16280, 10.1371/journal.pone.0016280 (PubMed PMID: 21297983 PubMed Central PMCID: PMCPMC3030572).
221. [221] Kim, J.K., Choi, S.J., Cho, H.Y., Hwang, H.J., Kim, Y.J., Lim, S.T., Kim, C.J., Kim, H.K., Peterson, S., Shin, D.H., Protective effects of kaempferol (3,4’,5,7-tetrahydroxyflavone) against amyloid beta peptide (Abeta)-induced neurotoxicity in ICR mice. Biosci. Biotechnol. Biochem. 74:2 (2010), 397–401, 10.1271/bbb.90585 (PubMed PMID: 20139605).
222. [222] Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., Pfeiffer, E., Sano, M., van Dyck, C.H., Thal, L.J., Alzheimer's Disease Cooperative Study G. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352:23 (2005), 2379–2388, 10.1056/NEJMoa050151 (PubMed PMID: 15829527).
223. [223] Dysken, M.W., Sano, M., Asthana, S., Vertrees, J.E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G.D., McCarten, J.R., Malphurs, J., Prieto, S., Chen, P., Loreck, D.J., Trapp, G., Bakshi, R.S., Mintzer, J.E., Heidebrink, J.L., Vidal-Cardona, A., Arroyo, L.M., Cruz, A.R., Zachariah, S., Kowall, N.W., Chopra, M.P., Craft, S., Thielke, S., Turvey, C.L., Woodman, C., Monnell, K.A., Gordon, K., Tomaska, J., Segal, Y., Peduzzi, P.N., Guarino, P.D., Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311:1 (2014), 33–44, 10.1001/jama.2013.282834 (PubMed PMID: 24381967 PubMed Central PMCID: PMCPMC4109898).
224. [224] Investigators NN-P, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:1 (2007), 20–28, 10.1212/01.wnl.0000250355.28474.8e (PubMed PMID: 17200487).
225. [225] Shults, C.W., Beal, M.F., Fontaine, D., Nakano, K., Haas, R.H., Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 50:3 (1998), 793–795 (PubMed PMID: 9521279).
226. [226] Kaufmann, P., Thompson, J.L., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L.S., Katz, J., Rollins, Y., Barohn, R.J., Jackson, C.E., Tiryaki, E., Lomen-Hoerth, C., Armon, C., Tandan, R., Rudnicki, S.A., Rezania, K., Sufit, R., Pestronk, A., Novella, S.P., Heiman-Patterson, T., Kasarskis, E.J., Pioro, E.P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., Levin, B., Group, Q.S., Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 66:2 (2009), 235–244, 10.1002/ana.21743 (PubMed PMID: 19743457 PubMed Central PMCID: PMCPMC2854625).
227. [227] Baum, L., Lam, C.W., Cheung, S.K., Kwok, T., Lui, V., Tsoh, J., Lam, L., Leung, V., Hui, E., Ng, C., Woo, J., Chiu, H.F., Goggins, W.B., Zee, B.C., Cheng, K.F., Fong, C.Y., Wong, A., Mok, H., Chow, M.S., Ho, P.C., Ip, S.P., Ho, C.S., Yu, X.W., Lai, C.Y., Chan, M.H., Szeto, S., Chan, I.H., Mok, V., Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 28:1 (2008), 110–113, 10.1097/jcp.0b013e318160862c (PubMed PMID: 18204357).
228. [228] Singer, C., Tractenberg, R.E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., Thal, L.J., Alzheimer's Disease Cooperative S. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26:7 (2003), 893–901 (PubMed PMID: 14655926; PubMed Central PMCID).
229. [229] Schapira, A.H., McDermott, M.P., Barone, P., Comella, C.L., Albrecht, S., Hsu, H.H., Massey, D.H., Mizuno, Y., Poewe, W., Rascol, O., Marek, K., Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 12:8 (2013), 747–755, 10.1016/S1474-4422(13)70117-0 (PubMed PMID: 23726851 PubMed Central PMCID: PMCPMC3714436).
230. [230] Holmay, M.J., Terpstra, M., Coles, L.D., Mishra, U., Ahlskog, M., Oz, G., Cloyd, J.C., Tuite, P.J., N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin. Neuropharmacol. 36:4 (2013), 103–106, 10.1097/WNF.0b013e31829ae713 (PubMed PMID: 23860343 PubMed Central PMCID: PMCPMC3934795).
231. [231] Cudkowicz, M.E., van den Berg, L.H., Shefner, J.M., Mitsumoto, H., Mora, J.S., Ludolph, A., Hardiman, O., Bozik, M.E., Ingersoll, E.W., Archibald, D., Meyers, A.L., Dong, Y., Farwell, W.R., Kerr, D.A., Investigators, E., Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 12:11 (2013), 1059–1067, 10.1016/S1474-4422(13)70221-7 (PubMed PMID: 24067398).